乌苯美司对恶性肿瘤患者免疫功能的影响研究  

The effect of Ubenimex on the immunity of patients with malignant tumor

作　　者：曹华[1,2] 郑涛[1,2] 许瑞莲[1,2] 陈亦欣[1,2] 王树滨[1,2] 闫茂生[1,3] 

机构地区：[1]暨南大学第二临床医学院 [2]深圳市人民医院肿瘤内科,深圳市518020 [3]深圳市人民医院放疗科,深圳市518020

出　　处：《中国肿瘤临床与康复》2012年第3期196-200,共5页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的在治疗过程中动态检测患者外周血T淋巴细胞核仁形成区嗜银蛋白(Ag-NORs)含量,探讨乌苯美司对恶性肿瘤患者免疫功能的影响。方法 154例患者为乌苯美司治疗组,用法为30mg/d,早晨空腹1次口服或分3次口服,连续应用,中位治疗时间为3个月;另有50例患者为未治疗组和30例正常人组,所有患者均同期应用化疗。以外周血T淋巴细胞Ag-NORs含量(I/S%值)为评价免疫功能状况的指标,对所有入组者进行检测,对治疗组应用乌苯美司前后的Ag-NORs含量进行动态观察,并采用SPSS 17.0统计软件进行分析。结果正常人外周血T淋巴细胞Ag-NORs含量高于化疗前治疗组和未治疗组患者(P<0.01),而治疗组与未治疗组间差异无统计学意义(P>0.05);治疗组患者应用乌苯美司后Ag-NORs含量较用药前明显提高(P<0.05),与正常人差异也无统计学意义(P>0.05);未治疗组患者化疗前后Ag-NORs含量变化差异无统计学意义(P>0.05)。结论恶性肿瘤患者存在明显的免疫功能下降,服用乌苯美司可提高肿瘤患者的免疫功能。Objective To study the effect of Ubenimex on the immunity of patients with malignant tumor by detecting the changes of the nucleolar organizer regions argyrophilic protein（ Ag - NORs） in periph- eral blood T lymphocyte. Methods 154 patients with Ubenimex regimen took tablets with doses of 10mg three times or 30mg once a day. The median time of treatment was 3 months. In addition, there were 50 pa- tients without Ubenimex regimen and 30 cases of health controls. All patients were treated by chemotherapy. The number of Ag - NORs of peripheral blood T lymphocyte was used as a marker for monitoring immune ac- tivity. All cases were detected by the number of Ag - NORs of peripheral blood T lymphocyte, and the pa- tients with Ubenimex regimen were monitored by the change of Ag - NORs. The outcome was analyzed by SPSS 17. 0 software. Results The number of Ag - NORs of peripheral blood T lymphocyte in the health controls was higher than that in patients before therapy（ P 〈 0.01 ）, and there was no difference between the treatment group and the non - treatment group before therapy （ P 〉 0. 05 ）. The number of Ag - NORs after administration of Ubenimex was higher than that before therapy （ P 〈 0. 05 ）, and was similar with that of health controls （ P 〉 0. 05 ）. There was no significant change in the number of Ag - NORs in the non - treat- ment group （P 〉 0. 05 ）. Conclusions Patients with malignant tumor show significant immunodeficiency compared with healthy controls, and Ubenimex may play a role in enhancing immune activity in patients.

关 键 词：肿瘤 乌苯美司 免疫功能 核仁形成区嗜银蛋白(Ag-NORs) 

分 类 号：R730.5[医药卫生—肿瘤]